Evidence map›Paper›PMID 29383961›Full record

ArticleDrug delivery2018

Nano-engineered microcapsules boost the treatment of persistent pain.

Olga Kopach, Kayiu Zheng, Luo Dong, Andrei Sapelkin, Nana Voitenko, Gleb B Sukhorukov, Dmitri A Rusakov

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Global research trends of nanotechnology for pain management.Frontiers in bioengineering and biotechnology · 2023
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. CaInternational journal of molecular sciences · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Quaternary Lidocaine Derivatives: Past, Present, and Future.Drug design, development and therapy · 2021
    Review
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Olga Kopacha Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology , University College London , London , UK.
Kayiu Zhenga Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology , University College London , London , UK.
Luo Dongb School of Engineering and Materials Science , Queen Mary University of London , London , UK.
Andrei Sapelkinc Centre for Condensed Matter and Materials Physics , Queen Mary University of London , London , UK.
Nana Voitenkod Department of Sensory Signaling , Bogomoletz Institute of Physiology , Kyiv , Ukraine.
Gleb B Sukhorukovb School of Engineering and Materials Science , Queen Mary University of London , London , UK.
Dmitri A Rusakova Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology , University College London , London , UK.
Queen Mary University of London · GBUniversity College London · GBBogomoletz Institute of Physiology · UA

Funding

Medical Research Council G0600368Medical Research Council G0802216Medical Research Council G0900613Wellcome Trust 212251/Z/18/Z
6 · The paper itself

Abstract

Persistent pain remains a major health issue: common treatments relying on either repeated local injections or systemic drug administration are prone to concomitant side-effects. It is thought that an alternative could be a multifunctional cargo system to deliver medicine to the target site and release it over a prolonged time window. We nano-engineered microcapsules equipped with adjustable cargo release properties and encapsulated the sodium-channel blocker QX-314 using the layer-by-layer (LbL) technology. First, we employed single-cell electrophysiology to establish in vitro that microcapsule application can dampen neuronal excitability in a controlled fashion. Secondly, we used two-photon excitation imaging to monitor and adjust long-lasting release of encapsulated cargo in target tissue in situ. Finally, we explored an established peripheral inflammation model in rodents to find that a single local injection of QX-314-containing microcapsules could provide robust pain relief lasting for over a week. This was accompanied by a recovery of the locomotive deficit and the amelioration of anxiety in animals with persistent inflammation. Post hoc immunohistology confirmed biodegradation of microcapsules over a period of several weeks. The overall remedial effect lasted 10-20 times longer than that of a single focal drug injection. It depended on the QX-314 encapsulation levels, involved TRPV1-channel-dependent cell permeability of QX-314, and showed no detectable side-effects. Our data suggest that nano-engineered encapsulation provides local drug delivery suitable for prolonged pain relief, which could be highly advantageous compared to existing treatments.

Indexed as

Anesthetics, LocalAnimalsAnimals, NewbornCells, CulturedChronic PainDrug Delivery SystemsHippocampusLidocaineMaleNanocapsulesRatsRats, Sprague-DawleyRats, WistarTreatment OutcomeAnesthetics, LocalLidocaineNanocapsulesQX-314Biodegradable microcapsulesdrug diffusionlocomotive deficit and anxietyNa+ channelsneuronal excitabilitypain reliefpersistent pain

Identifiers

PMID29383961
PMCPMC5796488
OpenAlexW2790272202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.